Calpain-mediated integrin deregulation as a novel mode of action for the anticancer gallium compound KP46

Molecular Cancer Therapeutics

Volumn 13, Issue 10, 2014, Pages 2436-2449

  Jungwirth, Ute ^a,e   Gojo, Johannes ^a,c   Tuder, Theresa ^a   Walko, Gernot ^b,f   Holcmann, Martin ^a   Schöfl, Thomas ^a   Nowikovsky, Karin ^c   Wilfinger, Nastasia ^c   Schoonhoven, Sushilla ^a   Kowol, Christian R ^d   Lemmens Gruber, Rosa ^c   Heffeter, Petra ^a,d   Keppler, Bernhard K ^d   Berger, Walter ^a,d  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b MAX F PERUTZ LABORATORIES   (Austria)

^c MEDICAL UNIVERSITY OF VIENNA   (Austria)

^d UNIVERSITY OF VIENNA   (Austria)

^e INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^f GUY S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA5 INTEGRIN; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC METAL COMPLEX; ARGININE; ASPARTIC ACID; BETA1 INTEGRIN; BETA4 INTEGRIN; BETA5 INTEGRIN; CALPAIN; CASPASE INHIBITOR; COLLAGEN TYPE 1; FOCAL ADHESION KINASE; GLYCINE; MAGNESIUM ION; PD 150606; PROTEIN BAX; PROTEIN BCL 2; PROTEIN P53; TALIN; TRIS(8 QUINOLINOLATO)GALLIUM(III); UNCLASSIFIED DRUG; 8 QUINOLINOL; INTEGRIN; ORGANOMETALLIC COMPOUND; TRIS(8-QUINOLINOLATO)GALLIUM (III);

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CANCER RESISTANCE; CELL ADHESION; CELL DEATH; CELL MEMBRANE; CELL VIABILITY; CELLULAR DISTRIBUTION; COLON CANCER; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVITY; FEMALE; FOCAL ADHESION; HCT116 CELL LINE; HUMAN; HUMAN CELL; IC50; IN VITRO STUDY; IN VIVO STUDY; LUNG CANCER; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN CLEAVAGE; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN STABILITY; TREATMENT DURATION; TUMOR NECROSIS; TUMOR XENOGRAFT; UPREGULATION; ANALOGS AND DERIVATIVES; ANIMAL; BAGG ALBINO MOUSE; CACO 2 CELL LINE; DRUG EFFECTS; DRUG SCREENING; METABOLISM; NEOPLASMS; RANDOMIZATION; SCID MOUSE; TUMOR CELL LINE;

ANIMALS; CACO-2 CELLS; CALPAIN; CELL ADHESION; CELL LINE, TUMOR; FEMALE; HUMANS; INTEGRINS; MICE; MICE, INBRED BALB C; MICE, SCID; NEOPLASMS; ORGANOMETALLIC COMPOUNDS; OXYQUINOLINE; RANDOM ALLOCATION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84926625436     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-14-0087     Document Type: Article

References (47)

1. Sava G, Jaouen G, Hillard EA, Bergamo A. Targeted therapy vs. DNA-adduct formation-guided design: thoughts about the future of metal-based anticancer drugs. Dalton Trans 2012;41:8226-34.
2. Jungwirth U, Kowol CR, Keppler BK, Hartinger CG, Berger W, Heffeter P. Anticancer activity of metal complexes: involvement of redox processes. Antioxid Redox Signal 2011;15:1085-127.
3. Heffeter P, Jungwirth U, Jakupec M, Hartinger C, Galanski M, Elbling L, et al. Resistance against novel anticancer metal compounds: differences and similarities. Drug Resist Updat 2008;11:1-16.
4. Chitambar CR, Antholine WE. Iron-targeting antitumor activity of gallium compounds and novel insights into triapine((R))-metal complexes. Antioxid Redox Signal 2013;18:956-72.
5. Warrell RPJr, Lovett D, Dilmanian FA, Schneider R, Heelan RT. Low-dose gallium nitrate for prevention of osteolysis in myeloma: results of a pilot randomized study. J Clin Oncol 1993;11:2443-50.
6. Warrell RPJr, Alcock NW, Bockman RS. Gallium nitrate inhibits accelerated bone turnover in patients with bone metastases. J Clin Oncol 1987;5:292-8.
7. Bernstein LR, Tanner T, Godfrey C, Noll B. Chemistry and pharmacokinetics of gallium maltolate, a compound with high oral gallium bioavailability. Metal Based Drugs 2000;7:33-47.
8. Collery P, Keppler B, Madoulet C, Desoize B. Gallium in cancer treatment. Crit Rev Oncol Hematol 2002;42:283-96.
9. Hofheinz RD, Dittrich C, Jakupec MA, Drescher A, Jaehde U, Gneist M, et al. Early results from a phase I study on orally administered tris(8-quinolinolato)gallium(III) (FFC11, KP46) in patients with solid tumors-a CESAR study (Central European Society for Anticancer Drug Research-EWIV). Int J Clin Pharmacol Ther 2005;43:590-1.
10. Hummer AA, Heffeter P, Berger W, Filipits M, Batchelor D, Buchel GE, et al. X-ray absorption near edge structure spectroscopy to resolve the in vivo chemistry of the redox-active indazolium trans-[Tetrachlorobis (1H-indazole)ruthenate(III)] (KP1019). J Med Chem 2013;56:1182-96.
11. Thiel M, Schilling T, Gey D, Ziegler R, Collery P, Keppler B. Tris(8-quinolinolato)gallium(III), a novel orally applied antitumor gallium compound. Relevance of Tumor Models for Anticancer Drug Development. Contrib Oncol Basel, Karger 1999;54:439-43.
12. Collery P, Domingo JL, Keppler BK. Preclinical toxicology and tissue gallium distribution of a novel antitumour gallium compound: tris (8-quinolinolato) gallium (III). Anticancer Res 1996;16:687-91.
13. Chitambar CR. Gallium-containing anticancer compounds. Future Med Chem 2012;4:1257-72.
14. Zijlstra JG, de Vries EG, Mulder NH. Multifactorial drug resistance in an adriamycin-resistant human small cell lung carcinoma cell line. Cancer Res 1987;47:1780-4.
15. Mathieu V, Pirker C, Schmidt WM, Spiegl-Kreinecker S, Lotsch D, Heffeter P, et al. Aggressiveness of human melanoma xenograft models is promoted by aneuploidy-driven gene expression deregulation. Oncotarget 2012;3:399-413.
16. Heffeter P, Jakupec MA, Korner W, Chiba P, Pirker C, Dornetshuber R, et al. Multidrug-resistant cancer cells are preferential targets of the new antineoplastic lanthanum compound KP772 (FFC24). Biochem Pharmacol 2007;73:1873-86.
17. Lotsch D, Steiner E, Holzmann K, Spiegl-Kreinecker S, Pirker C, Hlavaty J, et al. Major vault protein supports glioblastoma survival and migration by upregulating the EGFR/PI3K signalling axis. Oncotarget 2013;4:1904-18.
18. Heffeter P, Pongratz M, Steiner E, Chiba P, Jakupec MA, Elbling L, et al. Intrinsic and acquired forms of resistance against the anticancer ruthenium compound KP1019 [indazolium trans-[tetrachlorobis(1H-indazole) ruthenate (III)] (FFC14A). J Pharmacol Exp Ther 2005;312:281-9.
19. Walko G, Vukasinovic N, Gross K, Fischer I, Sibitz S, Fuchs P, et al. Targeted proteolysis of plectin isoform 1a accounts for hemidesmosome dysfunction in mice mimicking the dominant skin blistering disease EBS-Ogna. PLoS Genet 2011;7:e1002396.
20. Kamyar MR, Kouri K, Rawnduzi P, Studenik C, Lemmens-Gruber R. Effects of moniliformin in presence of cyclohexadepsipeptides on isolated mammalian tissue and cells. Toxicol In Vitro 2006;20:1284-91.
21. Fischer H, Taylor N, Allerstorfer S, Grusch M, Sonvilla G, Holzmann K, et al. Fibroblast growth factor receptor-mediated signals contribute to the malignant phenotype of non-small cell lung cancer cells: therapeutic implications and synergismwith epidermal growth factor receptor inhibition. Mol Cancer Ther 2008;7:3408-19.
22. Hoda MA, Mohamed A, Ghanim B, Filipits M, Hegedus B, Tamura M, et al. Temsirolimus inhibits malignant pleural mesothelioma growth in vitro and in vivo: synergism with chemotherapy. J Thorac Oncol 2011;6:852-63.
23. Valiahdi SM, Heffeter P, Jakupec MA, Marculescu R, Berger W, Rappersberger K, et al. The gallium complex KP46 exerts strong activity against primary explanted melanoma cells and induces apoptosis in melanoma cell lines. Melanoma Res 2009;19:283-93.
24. Gogna R, Madan E, Keppler B, Pati U. Gallium compound GaQ(3)-induced Ca(2+) signalling triggers p53-dependent and -independent apoptosis in cancer cells. Br J Pharmacol 2012;166:617-36.
25. Cunningham KE, Turner JR. Myosin light chain kinase: pulling the strings of epithelial tight junction function. Ann N Y Acad Sci 2012;1258:34-42.
26. Hynes RO. Integrins: bidirectional, allosteric signaling machines. Cell 2002;110:673-87.
27. Zhong X, Rescorla FJ. Cell surface adhesion molecules and adhesion-initiated signaling: understanding of anoikis resistance mechanisms and therapeutic opportunities. Cell Signal 2012;24:393-401.
28. Hu P, Luo BH. Integrin bi-directional signaling across the plasma membrane. J Cell Physiol 2013;228:306-12.
29. Zhang K, Chen J. The regulation of integrin function by divalent cations. Cell Adhes Migr 2012;6:20-9.
30. Franco SJ, Huttenlocher A. Regulating cell migration: calpains make the cut. J Cell Sci 2005;118:3829-38.
31. Storr SJ, Carragher NO, Frame MC, Parr T, Martin SG. The calpain system and cancer. Nat Rev Cancer 2011;11:364-74.
32. Vazquez A, Bond EE, Levine AJ, Bond GL. The genetics of the p53 pathway, apoptosis and cancer therapy. Nat Rev Drug Discov 2008;7:979-87.
33. Cramer LP, Mitchison TJ. Investigation of the mechanism of retraction of the cell margin and rearward fl ow of nodules during mitotic cell rounding. Mol Biol Cell 1997;8:109-19.
34. Maddox AS, Burridge K. RhoA is required for cortical retraction and rigidity during mitotic cell rounding. J Cell Biol 2003;160:255-65.
35. Desgrosellier JS, Cheresh DA. Integrins in cancer: biological implications and therapeutic opportunities. Nat Rev Cancer 2010;10:9-22.
36. Xiong JP, Stehle T, Zhang R, Joachimiak A, Frech M, Goodman SL, et al. Crystal structure of the extracellular segment of integrin alpha Vbeta3 in complex with an Arg-Gly-Asp ligand. Science 2002;296:151-5.
37. Galluzzi L, Vitale I, Abrams JM, Alnemri ES, Baehrecke EH, Blagosklonny MV, et al. Molecular definitions of cell death subroutines: recommendations of the Nomenclature Committee on Cell Death 2012. Cell Death Differ 2012;19:107-20.
38. Taddei ML, Giannoni E, Fiaschi T, Chiarugi P. Anoikis: an emerging hallmark in health and diseases. J Pathol 2012;226:380-93.
39. Chiarugi P, Giannoni E. Anoikis: a necessary death program for anchorage-dependent cells. Biochem Pharmacol 2008;76:1352-64.
40. Lomonaco SL, Finniss S, Xiang C, Lee HK, Jiang W, Lemke N, et al. Cilengitide induces autophagy-mediated cell death in glioma cells. Neuro Oncol 2011;13:857-65.
41. Enyedy EA, Domotor O, Varga E, Kiss T, Trondl R, Hartinger CG, et al. Comparative solution equilibrium studies of anticancer gallium(III) complexes of 8-hydroxyquinoline and hydroxy(thio)pyrone ligands. J Inorg Biochem 2012;117:189-97.
42. Madan E, Gogna R, Keppler B, Pati U. p53 increases intra-cellular calcium release by transcriptional regulation of calcium channel TRPC6 in GaQ3-treated cancer cells. PLoS ONE 2013;8:e71016.
43. Lopatniuk P, Witkowski JM. Conventional calpains and programmed cell death. Acta Biochim Pol 2011;58:287-96.
44. Pinon JD, Labi V, Egle A, Villunger A. Bim and Bmf in tissue homeostasis and malignant disease. Oncogene 2008;27:S41-52.
45. Su LT, Agapito MA, Li M, Simonson WT, Huttenlocher A, Habas R, et al. TRPM7 regulates cell adhesion by controlling the calcium-dependent protease calpain. J Biol Chem 2006;281:11260-70.
46. Kunzelmann-Marche C, Freyssinet JM, Martinez MC. Regulation of phosphatidylserine transbilayer redistribution by store-operated Ca2+entry: role of actin cytoskeleton. J Biol Chem 2001;276:5134-9.
47. Aussel C, Marhaba R, Pelassy C, Breittmayer JP. Submicromolar La3+concentrations block the calcium release-activated channel, and impair CD69 and CD25 expression in CD3- or thapsigargin-activated Jurkat cells. Biochem J 1996;313:909-13.